CRNX Analyst Ratings
Crinetics Pharmaceuticals, Inc. (CRNX) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $9.01B, listed on NASDAQ, employing roughly 594 people, carrying a beta of 0.13 to the broader market. Crinetics Pharmaceuticals, Inc. Led by R. Scott Struthers, public since 2018-07-18.
Analyst Ratings
In the September 2026 monthly count, 14 analysts rated CRNX: 0 Strong Buy, 1 Buy, 13 Hold, 0 Sell and 0 Strong Sell.
Twelve months earlier, in September 2025: 18 analysts, 5 Strong Buy, 11 Buy, 2 Hold, 0 Sell and 0 Strong Sell.
Price Targets
- Average Target
- $84.86
- Median Target
- $85.00
- High
- $85.00
- Low
- $84.00
- Targets Published, Last 12 Months
- 17
Recent Price Targets
The 5 most recent of 17 price targets published in the last 12 months.
| Date | Firm | Analyst | Target | Price When Posted |
|---|---|---|---|---|
| Jul 28, 2026 | UBS | Not named | $85.00 | $83.85 |
| Jul 8, 2026 | Stifel Nicolaus | Alex Thompson | $85.00 | $83.50 |
| Jul 8, 2026 | Evercore ISI | Not named | $85.00 | $83.53 |
| Jul 7, 2026 | Jefferies | Not named | $85.00 | $42.03 |
| Jul 7, 2026 | H.C. Wainwright | Not named | $85.00 | $42.03 |
Recent Upgrades & Downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 28, 2026 | UBS | downgrade | Buy | Neutral |
| Jul 8, 2026 | TD Cowen | downgrade | Buy | Hold |
| Jul 8, 2026 | Evercore ISI Group | downgrade | Outperform | In Line |
| Jul 7, 2026 | HC Wainwright & Co. | downgrade | Buy | Neutral |
| Jul 7, 2026 | Jones Trading | downgrade | Buy | Hold |
How to Read CRNX Analyst Coverage
Sell-side equity analysts publish three primary outputs: ratings (Strong Buy / Buy / Hold / Sell / Strong Sell, or firm-specific equivalents), price targets, and EPS / revenue estimate revisions. Rating consensus moves slowly relative to price; it reflects 12-month directional conviction rather than near-term momentum. Price targets are more responsive but typically drift behind realized price during sharp moves. The most actionable signal for options traders is a cluster of ratings actions across multiple firms within a short window, which compresses or expands implied volatility on a horizon of days to weeks and shifts the put-call skew toward the directional consensus. The recent-actions table above shows the five most recent firm-level changes; longer histories live behind aggregator sources.
For event-driven options sizing, pair the consensus rating and target distribution with the implied-volatility surface and dealer-positioning view. Aggressive target hikes from multiple firms tend to tighten put skew (downside protection becomes relatively cheaper); aggressive cuts widen put skew. The size of the IV response in the hours after a rating change is visible on the per-ticker volatility skew page and the gamma-exposure page, both of which show how dealer hedging propagates the analyst-driven flow into the listed options chain.
Learn how analyst ratings is reported and how to read the data →